National Agency for Medicines and Medical Devices (NAMMD) of Romania Under various former names for over five decades, the Agency has undoubtedly played a key role in setting a regulatory framework for Romania’s pharmaceutical market. Over these five decades, thorough changes in the political regime, subsequent regulatory changes, the emergence of new institutions, and many other factors have drastically changed…
Celgene UK and Ireland Celgene just announced very impressive second quarter results for its global operations, with a 38% increase in revenue partly led by strong growth in Europe. Within the global performance of the company, how would you assess the performance of the UK in 2010/2011? This year has been somewhat of a…
Association of Producers of generic medicines in Romania (APMGR) APMGR is obviously a rather young association that has only really been active since about a year now. Can you first comment on the timing that the Association was called into life? The timing has been quite good, as the generics industry is currently experiencing a strong momentum. Every country,…
Genzyme Chile Genzyme was first established in Chile in 2004 but only opened its sales office in 2008, what was the rationale for the opening of the office at this time considering that you had been present in neighbouring countries 10 years before? The Chilean market is a very difficult one. We…
Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…
Pró Genéricos When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote it.” At that time, generics penetration was around 10.5% – now it’s around 20%. Does this reflect some fundamental change…
Celgene Hungary The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies to be adjusting their strategies in this market? The government has a large majority in the parliament since 2 years,…
WestHolland Foreign Investment Agency (WFIA) WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the Life Sciences sector. What drives the agency to place so much effort on attracting investments in Life Sciences in the…
Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…
India Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in the rankings. How satisfied are you with the company’s performance in 2010? The company performed satisfactorily last year, showing good…
Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…
See our Cookie Privacy Policy Here
